HealthMedia acquires MySelfHelp site

Share this article:
HealthMedia, a realtionship marketing firm focus ing on behavioral change, has acquired consumer health Web site MySelfHelp.com. Financial terms of the deal were not disclosed.

HealthMedia CEO Ted Dacko told reporters the “multimillion-dollar deal” represents “a huge revenue opportunity” that rounds out HealthMedia's product line.

With the acquisition, HealthMedia adds the site's interactive behavioral health programs for depression, insomnia and other behavioral health conditions to its repertoire of client offerings.
HealthMedia currently provides pharma companies with online patient compliance tools and generates online materials for health plans and large employers to initiate a dialogue with employees on consumer health issues such as healthy lifestyle and smoking cessation.

“We intend to offer MySelfHelp programs not only through the traditional behavioral healthcare and employee assistance program (EAP) channels, but to healthcare organizations and employers as part of our core health and disease management offering,” Dacko added.

HealthMedia's clients include Pfizer, GlaxoSmithKline, AstraZeneca, Eli Lilly, Takeda, Kaiser Permanente and Cleveland Clinic.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.